Morning all, Craig McGlashan here with the Europe Wire from the London newsroom. The tariff news keeps coming but we’re hearing from sources that in the European mid-market at least, dealmakers are getting busy regardless. While things might not ramp up too much ahead of the usual summer slowdown, there’s confidence that the third quarter should be a busy one. Keeping with that theme, we have a deal in mid-market healthcare to report, as Gilde Healthcare combines two businesses in the world of functional near-infrared spectroscopy. Comeback European mid-market dealmaking is on the rise following a post-Liberation Day lull, with demand buoyed by interest from large-cap private equity firms, sources told PE Hub. But with opportunities at the bigger end of the market starting to resurface, those extra players might not be around for too long. Learn why in the premium version of the Wire, with comments from Tim Morris, London-based CEO of DC Advisory UK, and James Grimwood, partner at Debevoise & Plimpton’s corporate department and a member of its private equity and mergers and acquisitions groups. Combined health We’ve also got a fresh deal to report in the European mid-market this morning. Gilde Healthcare will combine Artinis Medical Systems and NIRx Medical Technologies, a dual transaction that the firm said will establish a “global leader” in functional near-infrared spectroscopy (fNIRS) products. Read about the companies' specializations and M&A plans in the premium version of the Wire. That’s everything from me today. Rafael Canton is on US Wire duty later today and Nina Lindholm will write to you from Europe tomorrow. Cheers, Craig Read the full Wire commentary on PE Hub ... | 